Other equities research analysts have also issued reports about the stock. Royal Bank of Canada set a $20.00 price objective on shares of OptiNose and gave the stock a buy rating in a report on Monday, August 12th. BMO Capital Markets decreased their target price on shares of OptiNose from $26.00 to $24.00 and set an outperform rating on the stock in a research note on Tuesday, August 13th. Finally, Zacks Investment Research downgraded shares of OptiNose from a buy rating to a hold rating in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $21.50.
OptiNose stock traded up $0.42 during mid-day trading on Friday, hitting $6.83. 230,685 shares of the company traded hands, compared to its average volume of 254,677. The stock has a market cap of $267.68 million, a price-to-earnings ratio of -2.55 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.43 and a current ratio of 6.60. OptiNose has a one year low of $4.44 and a one year high of $12.05. The stock has a fifty day moving average price of $7.07 and a 200-day moving average price of $7.73.
OptiNose (NASDAQ:OPTN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.66) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.09. The firm had revenue of $6.68 million during the quarter, compared to analyst estimates of $7.74 million. OptiNose had a negative net margin of 670.20% and a negative return on equity of 102.10%. Sell-side analysts predict that OptiNose will post -2.75 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada increased its stake in shares of OptiNose by 223.5% in the second quarter. Royal Bank of Canada now owns 38,174 shares of the company’s stock worth $270,000 after buying an additional 26,374 shares during the period. Susquehanna International Group LLP purchased a new position in OptiNose during the 2nd quarter valued at $77,000. UBS Asset Management Americas Inc. purchased a new position in OptiNose during the 2nd quarter valued at $72,000. Cubist Systematic Strategies LLC purchased a new position in OptiNose during the 2nd quarter valued at $82,000. Finally, Bank of America Corp DE increased its position in OptiNose by 8.1% during the 2nd quarter. Bank of America Corp DE now owns 105,689 shares of the company’s stock valued at $748,000 after purchasing an additional 7,944 shares during the period. 64.98% of the stock is currently owned by institutional investors.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Read More: What is a back-end load?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.